文献速递临床试验与 GCP真实世界研究与卫生经济

被动背部支撑外骨骼在物流与护理中的实用性与有效性:ELSA LogiCare随机对照试验方案

Practical applicability and effectiveness of passive, back-support exoskeletons in logistics and care: a randomized controlled trial protocol (ELSA LogiCare).
PubMed 文献 · Trials · 2026-07-14

ELSA LogiCare是一项多中心、平行设计、随机对照试验,计划招募120名参与者,按2:1随机分为干预组和对照组。干预组再按1:1随机使用两种被动背部支撑外骨骼之一,为期3个月;对照组照常无辅助工作。主要结局为外骨骼可行性与使用情况(包括每日穿戴时间),有效性结局为3个月后肌肉骨骼不适。

要点

  • 多中心随机对照试验,计划样本120人,干预组约80人、对照组约40人。
  • 干预组使用被动背部支撑外骨骼3个月,对照组无辅助工作。
  • 主要结局为可行性与每日穿戴时间;有效性结局为3个月后肌肉骨骼不适。

核心结论

  • 被动背部支撑外骨骼若有效融入工作环境,可能显著减轻体力负荷并有助于降低肌肉骨骼疾病风险。
  • 本试验方案旨在评估被动背部支撑外骨骼在物流与护理领域的实用性和中期效果。

研究设计与样本

  • ELSA LogiCare为多中心、平行设计、随机对照试验,采用开放标签,仅结局评估者和数据分析者设盲。
  • 计划招募总样本量120名参与者,按2:1随机分为干预组(约80人)和对照组(约40人)。
  • 干预组再按1:1随机分配使用两种被动背部支撑外骨骼模型之一,为期3个月;对照组照常无辅助工作。
  • 主要分析遵循意向性治疗原则,采用重复测量混合效应模型估计可行性与有效性结局随时间的变化。
  • 结局在基线、干预期间每4周及干预结束后立即评估。

主要发现

  • 主要结局聚焦外骨骼的可行性和使用情况,包括每日穿戴时间。
  • 有效性相关结局为3个月后肌肉骨骼主诉,采用Cornell肌肉骨骼不适问卷评估。
  • 次要结局包括体力与脑力负荷(NASA任务负荷指数)、工作满意度(哥本哈根心理社会问卷)、认知表现(Wiener测试系统)、疲劳(疲劳量表)、外骨骼接受度(技术承诺)、用户满意度(Quest 2.0)、用户体验与实施障碍(简短访谈)、因病缺勤、血压、体力活动(Fitbit/Garmin)及脱落。

临床怎么用

  • 研究结果可为物流与护理行业引入被动背部支撑外骨骼提供可行性与中期效果证据。
  • 过程评价有助于理解如何将被动背部支撑外骨骼成功整合到物流与护理工作环境中。

局限性

  • 原文未报告试验结果数据,仅描述研究方案。
  • 研究为开放标签设计,仅结局评估者和数据分析者设盲。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Musculoskeletal disorders (MSDs) are the leading work-related health issue in Europe. While passive back-support exoskeletons have shown promise in reducing physical strain in laboratory settings, their medium-term effects under real-world working conditions remain largely unexplored. This study will assess the applicability and the medium-term effects of passive back-support exoskeletons on MSDs in the logistics and healthcare sectors. METHODS: ELSA LogiCare is a multicenter, parallel-designed, randomized controlled trial. Participants will be randomly assigned in a 2:1 ratio to either an intervention group or a control group. The intervention group will be randomly assigned (1:1) to use one of two passive back-support exoskeleton models for 3 months, while the control group works unassisted as usual. We aim to recruit a total sample size of 120 participants, resulting in approximately 80 participants in the intervention group and 40 participants in the control group. Primary outcomes focus on feasibility and use of the exoskeleton, including daily wearing time. Effectiveness-related outcomes include musculoskeletal complaints after 3 months, assessed using the Cornell Musculoskeletal Discomfort Questionnaire. Secondary outcomes include physical and mental workload (NASA-Raw Task Load Index), job satisfaction (Copenhagen Psychosocial Questionnaire), cognitive performance (Wiener Testsystem), fatigue (Fatigue Scale), acceptance of exoskeletons (Technology Commitment), user satisfaction (Quest 2.0), user experience and implementation barriers (short interviews), absences due to illness, blood pressure, physical activity (Fitbit/Garmin) and dropouts. Outcomes will be assessed at baseline, every 4 weeks during, and immediately after the intervention. The study is open-label, with blinding applied to outcome assessors and data analysts only. Primary analyses will follow the intention-to-treat principle and will be conducted using mixed-effects models with repeated measures to estimate feasibility- and effectiveness-related outcomes over time. DISCUSSION: When effectively integrated into workplace environments, passive back-support exoskeletons have the potential to significantly alleviate physical strain and enhance efforts to reduce the risks associated with MSDs. Our process evaluation can also help to understand how passive back-support exoskeletons can be successfully integrated into the logistics and care sectors. TRIAL REGISTRATION: German Clinical Trials Register (DRKS) under the DRKS-ID: DRKS00036072.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sieber W, Voß J, Falz R, et al. Practical applicability and effectiveness of passive, back-support exoskeletons in logistics and care: a randomized controlled trial protocol (ELSA LogiCare). Trials. 2026. PMID: 42443998. doi:10.1186/s13063-026-09890-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。